LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Jenkins, V; Catt, S; Banerjee, S; Gourley, C; Montes, A; Solis-Trapala, I; Monson, K; Fallowfield, L (2013)
Publisher: Nature Publishing Group
Journal: British Journal of Cancer
Languages: English
Types: Article
Subjects: oncologists' views, maintenance therapy, Patient Acceptance of Health Care, Cancer Research, Oncology, advanced ovarian cancer, Medical Oncology, Ovarian Neoplasms, Physician's Practice Patterns, Survival Rate, female, Clinical Study, Great Britain, Middle Aged, Questionnaires, patients' views, Disease-Free Survival, chemotherapy treatments, supportive care, /dk/atira/pure/subjectarea/asjc/2700/2730, /dk/atira/pure/subjectarea/asjc/1300/1306, Quality of Life, Humans, Male, R1
Background:Most patients presenting with advanced ovarian cancer (AOC) eventually relapse. Symptom palliation, maintenance of quality of life (QoL) and prolongation of life are primary therapeutic goals.Methods:Sixty-six UK oncologists completed an online survey about AOC management. Two hundred and two patients were interviewed about care, treatment experiences and expectations.Results:Prior to diagnosis, 34% (69 out of 202) of women had 3 symptoms associated with AOC. Twenty-one per cent (43 out of 202) thought poor symptom recognition by general practitioners (GPs) delayed diagnosis. Amelioration of side effects experienced was variable, for example, only 54% (68 out of 127) distressed by alopecia had received sufficient information about it. Clinicians were asked 'What minimum gain in progression-free survival (PFS) would make you feel it worthwhile to offer maintenance therapy?'; 48% (24 out of 50) indicated 5-6 months, but 52% (26 out of 50) believed patients would find PFS of 3-4 months acceptable. When patients were presented with hypothetical scenarios, 33% (52 out of 160) would require 1-2 months extra life, 6% (10 out of 160) 3-4 months, 31% (49 out of 160) 5-6 months, and 31% (49 out of 160) 7 months. However, 86% (173 out of 202) would accept treatment that improved QoL without prolongation of life. When asked what was most important, 33% (67 out of 201) said QoL, 9% (19 out of 201) length of life and 57% (115 out of 201) said both were equally important.Conclusion:Clinicians' and patients' experiences, expectations and priorities about OC management may differ.British Journal of Cancer advance online publication 7 May 2013; doi:10.1038/bjc.2013.223 www.bjcancer.com.

Share - Bookmark

Cite this article